
Opinion|Videos|March 25, 2024
Widening the Therapeutic Window in The Management of Parkinson’s Disease
Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.
Advertisement
Episodes in this series
Timecodes:
1:20 Long-term challenges
2:58 Fluctuations in benefits
6:35 Therapeutic window
11:40 Amantadine ER for PD
14:33 Dyskinesia and treatment
18:18 Amantadine patients
23:14 Amantadine formulations
27:59 Early treatment & future
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Current Treatment Strategies for Dravet Syndrome
2
NeurologyLive®'s Conference Coverage, Oveporexton Displays Symptom Improvement in NT1, FDA Allows BLA for AMT-130 in HD
3
FDA Allows AMT-130 Huntington Disease Data to Support Planned BLA Submission Under Accelerated Approval Pathway
4
Beyond Motor Symptoms: The Power of Connection in Parkinson Disease
5
















